Please login to the form below

Not currently logged in

Pfizer reveals post Wyeth-merger structure

Pfizer has announced its plans for the structure of its research and commercial operations following its acquisition of Wyeth

Pfizer has announced its plans for the structure of its research and commercial operations following its acquisition of Wyeth.

The US giant plans to form two distinct research organisations; Dr Martin Mackay, the current leader of Pfizer Global Research & Development (PGRD), will head up the PharmaTherapeutics Research Group, which will focus on advancing both companies' small-molecule discovery legacy and Dr Mikael Dolsten, the current president of Wyeth Research, will head up the BioTherapeutics Research Group creating a broad and deep pipeline in vaccines, antibodies, proteins, peptides, nucleic acids and other novel modalities.

Pfizer chairman and CEO, Jeff Kindler, will oversee both groups, and Mackay and Dolsten will, as well as serving as presidents of their respective organisations, serve as members of Pfizer's executive leadership team.

Dr Emilio Emini, current head of Wyeth's Vaccine Research and Development, will join Pfizer as chief scientific officer, vaccine and research, along with Dr Menelas Pangalos, Wyeth's current head of discovery, who will take up the position of chief scientific officer, neuroscience research.

"Creating two distinct, but complementary, research organisations led by the top scientist from each company, will provide sharper focus, less bureaucracy and clearer accountability in drug discovery," Kindler said. "This structure powerfully states our commitment to becoming the industry leader in small molecules, large molecules and vaccines. Our approach to research will fuel our discovery efforts, inspire top talent and translate into high-impact new medicines for patients."

Pfizer and Wyeth agreed a cash-and-stock transaction worth $68bn in January 2009. The companies expect the transaction to close at the end of the Q3 or during Q4 2009. Until the acquisition is complete, staff will continue in their current roles.

8th April 2009


Featured jobs

Subscribe to our email news alerts


Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....